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DEATHS CAUSED BY MALARIA IN SWITZERLAND 1988–2002
DANIEL CHRISTEN, ROBERT STEFFEN, AND PATRICIA SCHLAGENHAUF*
University of Zurich Travel Clinic, Institute for Social and Preventive Medicine, Zurich, Switzerland
Abstract. Despite sophisticated intensive medicine, between one and three malaria-associated deaths occur annually
in Switzerland. In this retrospective study, 33 deaths (25 men and 8 women) caused by falciparum malaria reported in
Switzerland from 1988 to 2002 were analyzed. The case fatality ratio (CFR) for the falciparum infections for the 15-year
period was 1.2%, with a peak of 2.2% in 1991. Sub-Saharan Africa was the source of all the imported fatal infections.
Non-immune Europeans had a significantly higher case fatality ratio than the non-Europeans (1.7% versus 0.2%; P <
0.001). Careless use or non-use of prophylaxis, sometimes because of physicians giving unsatisfactory pre-travel advice,
and initially missed diagnosis post-travel were factors that contributed to the development of severe infections leading
to death. Travelers should be sensitized to the risk of malaria by well-informed general practitioners. Updated infor-
mation is readily available (www.safetravel.ch). Regarding diagnosis and treatment, greater physician awareness of the
disease is needed, and expert advice should be sought without hesitation. Rapid malaria tests may be a useful diagnostic
adjunct in centers where microscopic expertise is lacking. Falciparum malaria in a non-immune patient is an emergency
requiring immediate treatment.
INTRODUCTION
Malaria is not endemic in Switzerland, and reported cases
are usually imported by travelers or immigrants. Plasmodium
falciparum is the predominant and most dangerous of the
malaria species. Its widespread prevalence, high hospitaliza-
tion rate, and potentially rapid and lethal course explain why
malaria is one of the most important diseases in travelers. The
realistic main goal of malaria prevention in Switzerland is to
avoid falciparum infections and deaths. In this retrospective
survey, the deaths caused by falciparum malaria reported in
Switzerland from 1988 to 2002 were analyzed in their context
to find out the circumstances that resulted in the fatal out-
comes of these cases.
MATERIALS AND METHODS
In Switzerland, notification of malaria cases is mandatory,
and the current reporting system was created in 1974. In 1988,
the system was revised, and the reporting forms were slightly
modified. The discussion about this raised the attention of the
physicians to the notification system, and in the years after
1988, a consistently higher number of cases were reported
annually and more detailed data were collected. Therefore,
and for homogeneity reasons, the 15-year period from 1988 to
2002 was chosen for this study.
Usually, malaria is diagnosed both by physicians and labo-
ratories. They report the cases on standard notification forms.
Within 1 week, physicians have to complete a supplementary
form with more detailed questions regarding the geographical
origin of the infection, the use of chemoprophylaxis, and the
progression of the disease (this form can be downloaded in
French [http://www.bag-anw.admin.ch/infreporting/forms/d//
malaria_d.pdf] and German [http://www.bag-anw.admin.ch/
infreporting/forms/d//malaria_d.pdf]. All data are transferred
to the Swiss Federal Office of Public Health (SFOPH) to be
registered into a database, regularly analyzed, and published
as government reports in updates and annual bulletins (http://
www.bag.admin.ch/themen/medizin/00682/00684/01086/
index.html?langde, German; http://www.bag.admin.ch/
themen/medizin/00682/00684/01086/index.html?langfr,
French). These data were the basis of this study. Indepen-
dently, all deaths are reported through death certificates sent
to the Swiss Federal Office of Statistics (SFOS). In some
situations, only the SFOS was notified, and in these cases,
little epidemiologic data were available.
In a second step, hospitals in which fatal cases happened
were contacted. The case histories, clinical records, and inter-
views with some of the concerned physicians provided large
and detailed data of many of the fatal cases.
The detailed data on the fatal cases were analyzed, inter-
preted, and compared with the results and conclusions from
the analysis of the basic data from the SFOPH. Statistical
analysis was performed using the Mann-Whitney U test, and
significance was defined as P  0.05 (two-tailed). In this
study, all mixed infections notified to the SFOPH were
considered as falciparum infections if one of the species was
P. falciparum.
RESULTS
In the 15 years from 1988 to 2002, a total of 4,600 malaria
cases and 33 deaths were reported to the SFOPH (Table 1).
Two thousand eight hundred seventy-one (62.4%) of the in-
fections were caused by P. falciparum, and this species was
responsible for all of the 33 deaths; in two cases, there was
co-infection with P. vivax and P. malariae, respectively.
The case fatality ratio (CFR) of 1.2% for the falciparum
infections is the result of quite different CFRs of two sub-
groups: the Europeans, mostly white non-immune people,
and the non-Europeans, including a large number of immi-
grants from endemic countries. The fatality ratio of the Eu-
ropeans (27/1,610, 1.7%) was significantly (P < 0.001) higher
than the CFR calculated for the non-Europeans (2/970,
0.2%), explaining why the large and increasing proportion of
African nationals among the falciparum cases does not con-
tribute much to the deaths (Table 2).
The proportion of falciparum cases in the imported malaria
data is increasing, because of the growing number of infec-
tions imported from Africa. Falciparum cases imported from
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other continents are several-fold fewer and are decreasing
despite the even larger and increasing numbers of tourists
visiting these areas (Table 3). The increasing proportion of
falciparum infections imported by African nationals from Af-
rican countries is the reason for this trend among falciparum
cases. In contrast, there was a decline in the number of cases
imported by Swiss nationals.
Table 4 shows an overview of the fatal cases that were
notified during the observation period. This collective con-
sisted of 25 (75.8%) men and 8 (24.2%) women. The mean
age was 51.6 years (range, 26–80 years; outlier: 4-year-old
girl), which is 10–15 years above the annual means of ages for
falciparum cases in 1988–2002. Only two deaths of non-
Europeans were notified. Both of them, a 35-year-old man
from Ghana and a 4-year-old girl from former Zaïre, were
visiting relatives in their country of origin (so-called visiting
friends and relatives [VFRs]). The other imported infections
were acquired by Europeans, mostly traveling as tourists.
Sub-Saharan Africa was the source of all the imported infec-
tions, and Kenya was by far the most visited country among
them (15/25, 60%). Travel duration was known for 18 of the
cases. The mean travel duration was 14 days, and all travel
was in the range of a short-term stay in the endemic countries
(range, 2–30 days). Chemoprophylaxis was either not taken at
all (16/19, 84.2%) or on an irregular basis (2/19), which means
that these travelers either took a drug that was not recom-
mended in that situation or a recommended drug but did not
take it properly or discontinued the prophylaxis. The 4-year-
old girl traveling to former Zaïre used a chemoprophylaxis
with chloroquine/proguanil in 1996, when mefloquine was
considered to be more efficacious and was recommended also
for children > 5 kg. However, if there was a contraindication
against mefloquine (which is not known), chloroquine/
proguanil was recommended as a second choice at that time.
At least two travelers had been prescribed mefloquine by
their general practitioners but did not take it. A 52-year-old
woman traveled to Kenya without chemoprophylaxis after a
fatal misunderstanding with her general practitioner, al-
though she was aware of the risk of malaria.
The median duration between arrival in Switzerland and
symptom onset was 7 days (interquartile range, 10–3 days; 13
cases), although this onset can be much delayed, as illustrated
by the case of the 56-year-old man returning from Togo 2001
who fell ill no less than 55 days after his return to Switzerland.
The median duration from symptom onset until the establish-
ment of the correct diagnosis (patient’s and doctor’s delay)
was 5 days (interquartile range, 6.0–3.75; 20 cases). Because
the notification forms do not separate out these two different
kinds of delays, it was often difficult to identify them sepa-
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TABLE 2
Geographical origin of the patients with falciparum malaria in Swit-
zerland from 1988 to 2002
1988–2002 Percent
Annual
mean
1988–2002 Fatalities
CRFs
(%)
Falciparum malaria cases 2,871 100 191.4 33 1.2
Swiss nationals 1,428 49.7 95.2 22 1.5
Europeans (without Swiss) 182 6.3 12.1 5 2.8
Europeans (with Swiss) 1,610 56.1 107.3 27 1.7
non-Europeans 970 33.8 64.7 2 0.2
Unknown nationality 291 10.1 19.4 4 1.37
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rately with precision, but in many of the case histories, we
found typical patterns of mistakes and delays from both pa-
tients and doctors. An example for a prolonged delay is the
case of the 52-year-old man who traveled to Mombasa,
Kenya, in 2002. He used to travel twice a year to Africa for 20
years and thought that he was not at risk for malaria. Al-
though he suffered from continuous vomiting and diarrhea
for 4 days before returning to Switzerland, he hesitated 7 days
before seeking medical help, and when admitted to the hos-
pital, he was in a very poor condition and died the same night.
As for the doctor’s delay, we could observe that in 12 of 15
cases (80%) with that specific data, the correct diagnosis was
initially missed, mostly interpreted as harmless viral syn-
dromes, but without ruling out malaria as a differential diag-
nosis. A rapid test was only performed in two cases. At least
six of these patients were dismissed with a wrong diagnosis
and died within a maximum of 4 days at home without seeing
another doctor. Thirteen of these 15 patients (87%) sought
help from their general practitioner, presenting mostly with
flu-like symptoms such as fever, malaise, muscle aches, and
chills. A 27-year-old flight attendant presented to a travel
health practitioner and was immediately admitted to hospital,
whereas a 51-year-old woman directly presented at the hos-
pital with an orbital hematoma after she fell at home. She had
been to Kenya 2 weeks before, and when she deteriorated,
P. falciparum was found accidentally in a routine blood con-
trol. With the often rapid development of severe malaria,
various vital organs are affected, and the patients usually are
admitted to the intensive care unit (Table 5). The median
duration of symptomatic infection (symptom onset – death)
was 8 days (interquartile range, 10.0–5.5; 23 cases).
Because there are so many parallels within the cases, and
this is an important point in this study, we chose the case of
the 49-year-old man who used to travel for many years to
Kenya to show these common features of the fatal cases: 10
days after his return to Switzerland in January 1998, he
started to feel ill with rhinitis and dry cough and later devel-
oped malaise and chills; 2 days after symptom onset, he saw
his general practitioner, who sent him home with a suspected
viral syndrome. The same evening, the family noticed a wors-
ening of his mental state of the now anxious, confused, and
dysarthric patient and brought him to a regional hospital. In
a thick blood smear, malaria parasites were found but were
not attributed to P. falciparum. The clinical charts gave no
information of whether a thin blood smear was examined.
Expert advice was not sought immediately, and treatment
with antimalarials was not initiated because the patient
seemed to recover while being treated with antibiotics against
pneumonia. He claimed to have taken a regular chemopro-
phylaxis with mefloquine, but in a later examination, the
plasma level of the drug was zero. After 2 days at the hospital,
expert examination of the blood revealed parasitemia of 50%
with P. falciparum. On the same day, the condition of the man
worsened rapidly, he was transported to a larger hospital, and
died the next day of multiple organ failure.
Apart from the imported cases, two persons acquired in-
fection in Switzerland, namely a 53-year-old man, who lived
near the international airport of Geneva and probably was
bitten by a mosquito brought by plane from an endemic area
in July 1996, and a 70-year-old man, who was found to have
acquired a falciparum infection after he received large
amounts of blood products in the context of two operations in
1999.1,2 From 1988 to 2002, a total of 11 cases with unusual
transmission were notified, that is, eight cases of odyssean,
two cases of induced, and one case of congenital falciparum
malaria. Because there were two deaths in this category, the
calculated CFR was high (18.2%).
DISCUSSION
In our view, there are three principal findings of this study:
First, imported falciparum malaria is still so frequent in Swit-
zerland that every general practitioner is likely to be con-
fronted with this dangerous parasite, and infections are asso-
ciated with between one to three deaths per year. Second,
patients can be separated in two subgroups: the Europeans,
mostly traveling as tourists and with a high CFR, and the
non-Europeans, mainly African nationals, running a signifi-
cantly lower risk to die of malaria, but who are responsible for
the growing number of imported falciparum infections from
Africa because they tend to underestimate the risk of infec-
tion when their semi-immunity quickly wanes while living in
Switzerland. Third, after examining the clinical records of the
fatal cases, we pinpointed the key role of the general practi-
tioners to prevent deaths because they can influence the be-
TABLE 3
Origin of the imported falciparum infections in Switzerland from 1988 to 2002
1988–2002 Percent Annual means
Trends
1988–1993
1994–2000
(annual means) 2001–2002
Falciparum infections 2,871 100 191.4 157.3 211.6 223.0
Imported from
Africa 2,454 85.5 163.6 130.5 185.3 187.0
Asia 183 6.4 12.2 14.8 11.0 8.5
South America 49 1.7 3.3 4.2 2.9 2.0
Oceania 13 0.5 0.9 1.7 0.3 0.5
Others and unknown 172 6.0 11.5 6.2 12.1 25.0
Travelers from Switzerland 154.3* 100 11.0 9.9 11.9 11.4
To Africa 5.3 3.4 0.4 0.3 0.4 0.5
To Asia 7.3 4.7 0.5 0.5 0.6 0.6
To Oceania 0.8 0.5 0.1 0.1 0.1 0.1
To the Americas 9.6 6.2 0.7 0.6 0.8 0.7
Other (mostly Europe) 131.3 85.1 9.4 8.5 10.1 9.7
* Millions of travelers.
CHRISTEN AND OTHERS1190
havior of the traveler (before, during, and after travel) and
are crucial for rapid diagnosis and treatment.
When analyzing fatal cases caused by falciparum malaria,
almost every case is a complex entity of factors leading to
infection and death. This study clarified what these decisive
factors were, the circumstances that contributed to the deaths,
and how these fatalities could have been prevented. This
global approach seems to be at the same time a strength and
a weakness of this study.
This is a strength because the examination of all data about
the fatal cases of these years went beyond a case report and
allowed the identification of the most important key events
TABLE 5
Complications of 24 of the fatal cases caused by severe falciparum malaria in Switzerland 1988–2002
Type Frequency Manifestations
Neurological 67% Convulsions, confusion, impaired consciousness/coma, dysarthric speech
Pulmonary 58% Pulmonary edema/ARDS. In at least two cases, fluid management of the dehydrated patient was extremely
difficult because of the strong tendency to develop pulmonary edema.
Renal 50% Acute renal failure.
Cardiovascular 38% Cardiac arrest, circulatory collapse (twice associated with secondary bacteriological infection). In a patient that
was treated with high doses of catecholamines and quinine for days, a complicating fatal myocarditis was
diagnosed in the end. Two patients died of a pulmonary embolism.
Other 25–100% Hematologic (severe anemia, thrombocytopenia, bleeding, disseminated coagulation, jaundice) and metabolic
(hypoglycemia, acidosis) disorders as well as high fevers and dehydration could be found throughout the cases.
Secondary infections were found in at least six cases (25%).
TABLE 4
Epidemiologic and clinical data of the fatal P. falciparum infections from 1988 to 2002
Sex Age Nationality
Visited
countries Chemoprophylaxis
Time between
arrival in Switzerland
and onset of symptoms (d)
Time between
onset of symptoms
and correct diagnosis (d)
Time between
onset of symptoms
and death (d)
1988 M 78 n/a n/a n/a n/a n/a n/a
1988 M 69 n/a n/a n/a n/a n/a n/a
1988* F 68 CH Kenya Fansidar†, irregular 6 5 5
1989* M 70 CH Kenya None 4 5 23
1990 M 39 CH Kenya None 7 7 8
1990 M 45 D Kenya None 2 23‡ 15
1990 M 56 n/a n/a n/a n/a n/a n/a
1991 M 80 CH n/a n/a n/a 7 n/a
1991 M 26 Iceland Kenya n/a 14 6 10
1991 M 35 CH Kenya None n/a n/a n/a
1992 F 51 CH Kenya None 15 1 10
1992 M 35 Ghana Ghana n/a n/a 6 8
1993 F 45 CH Kenya None n/a 5 9
1993 M 33 D Ghana, Nigeria None n/a n/a n/a
1993 F 62 CH S. Africa, Botswana Fansidar, not taken n/a n/a n/a
1994 F 60 CH Kenya, Uganda Fansidar, irregular −3¶ 9 68¶
1994 M 46 CH n/a n/a n/a n/a n/a
1995 M 40 CH Mali, Benin None (homeopathic) n/a 8‡ 7
1995 F 27 CH Kenya n/a 8 3 11
1996 M 57 CH Kenya n/a 0 5 6
1996 M 53 CH Switzerland (None) (−) 1 3
1996 F 4¶ Former Zaı¨re Former Zaı¨re Chloroquine/proguanil 9 4 4
1997 M 60 CH Senegal None n/a 5 6
1998 M 49 CH Kenya None 10 2 5
1999 F 63 n/a S. Africa n/a n/a n/a n/a
1999 M 70 CH Switzerland (None) (−) 4 9
2000 M 52 CH Kenya None −4¶ 6 7
2000 M 42 CH Madagascar None 3 7‡§ 8
2000 M 33 CH Madagascar n/a −2¶ 3‡ 2
2001 M 56 CH Togo Mefloquine, not taken 55¶ n/a 20
2002 M 67 CH Kenya Mefloquine, not taken 12 4 7
2002 M 34 F Kenya None 0 8§ 18
2002 M 50 D n/a n/a n/a 0 0
Mean (±SD) 51.6 ± 14.8 6.9 ± 5.0 4.7 ± 2.4 8.8 ± 5.6
Median (IQR) 51.5 (62.25–39.75) 7 (10.0–3.0) 5 (6.0–3.75) 8 (10.0–5.5)
Number (n  32) (n  13) (n  20) (n  23)
* In these cases, co-infection with P. vivax (1988) and P. malariae (1989) has been microscopically confirmed.
† Fansidar  sulfadoxine/pyrimethamine.
‡ Microscopic diagnosis was made 2 or more days post-mortem. This data was excluded from the calculations.
§ In these cases, in addition to the microscopic laboratory diagnosis, a rapid test was performed.
¶ Excluded outliers.
n/a, no data available; IQR, interquartile range; CH, Switzerland; D, Germany; F, France.
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associated with these fatal outcomes. This is a weakness be-
cause, with such a broad approach, it is impossible to provide
statistically significant evidence about many of the conclu-
sions we drew that go deeper into the complex mechanisms of
traveler’s malaria than just morbidity and mortality. This
needs a much more specific approach and appropriate data
collection from the beginning other than that used in this
retrospective study.
There is no statistical evidence in our study that, for ex-
ample, the patients who died of malaria had poorer pre-travel
advice, longer patient’s delays, or more missed diagnosis than
the others. The calculated CFR of 1.2% for falciparum infec-
tions is comparable with the average CFRs reported from
other countries of Europe in these years.3,4 However, com-
paring the CFRs in different countries can be difficult, be-
cause different notification systems and profiles of patients
can strongly affect these values. Furthermore, in addition to
some under-reporting in Switzerland, many infections in
Swiss nationals or residents are diagnosed and treated in for-
eign and endemic countries without being reported to the
SFOPH and do not appear in our statistics.5
Non-immune Europeans traveling as tourists accounted for
almost all of the deaths, and severe infection and fatalities
among this group remain a regular event. Fortunately, this
group has a slightly decreasing trend. The non-Europeans had
a significantly lower CFR than the Europeans. This might be
because, due to their acquired semi-immunity, the inflamma-
tory response to the parasite is limited and the disease is less
severe (clinical immunity), and they often have lower para-
sitemic levels than those recorded in non-immune travelers
(anti-parasite immunity). However, many of them are not
aware that this semi-immunity wanes quickly when they are
not exposed to mosquito bites in Switzerland. An Italian
study identified these patients, mostly traveling to their coun-
tries of origin to VFRs as a high-risk group for malaria infec-
tions because they tend to underestimate the risk of infection
and rarely take any chemoprophylaxis.6 We observed that, in
Switzerland from 1988 to 2002, the number of falciparum
malaria cases in migrants steadily increased.
The mean age of the fatal cases exceeded the annual means
by 10–15 years, which is in line with a recent study that iden-
tified age as a risk factor for fatal outcome of falciparum
malaria.7
All imported infections were acquired in Sub-Saharan Af-
rica, particularly in Kenya. This and generally the very few
numbers of notified falciparum infections imported from out-
side the African continent show the lower risk in areas be-
sides Africa—except some high risk regions—as well as the
appropriateness of the current Swiss prevention strategies for
all these areas, including the recommendation of emergency
stand-by-emergency treatment (SBET) for low-risk areas.
Typical patterns and key events were found in the case
histories that were associated with fatal outcome involved
both travelers and physicians.
Even if in many cases the reasons for not taking or discon-
tinuing chemoprophylaxis was not known, it is remarkable
that none of the travelers in our study performed a correct
and recommended prophylaxis (except the 4-year-old girl
who used a second-choice drug). General practitioners should
acquaint travelers with the disease and be in a position to
provide travelers with clear and balanced information about
anti-malarial drugs and mosquito bite protection. In 1997, a
study regarding German and Swiss general practitioners con-
cluded that many of them gave incorrect or unsatisfactory
pre-travel advice deviating from the current recommenda-
tions, leading to misunderstandings and confusion, with the
consequences that prescribed drugs are not taken or discon-
tinued prematurely.8 Current information on the recommen-
dations is readily available (www.bag.admin.ch/infekt/reise/f
[French], www.bag.admin.ch/infekt/reise/d [German], or
www.safetravel.ch) and is also comprehensible and recom-
mended for the informed traveler. Travelers who do not seek
medical advice rely mainly on recommendations of travel op-
erators, friends, or experiences, and often drugs that are no
longer up-to-date and less efficacious are taken. They are
often unaware or have a false perception of the tolerability
profiles of anti-malarial medications.9 General practitioners
should be aware that they can greatly influence opinions
about anti-malarial drugs in the population.10 It is also very
important to advise the traveler how to react in case of illness
after the return, because this will reduce the patient’s delay.
After infection, the first symptoms appeared on average 8
days (median, 6 days) after arrival in Switzerland. Physicians
should question febrile patients about travel history. Early
symptoms are very unspecific and not often not indicative of
malaria or severe illness. This may also be a reason why pa-
tients often did not quickly seek medical help unless they had
been instructed so earlier. In some cases, this led to extreme
patient’s delays.
Most patients presented first to a general practitioner, and
the diagnosis was initially very often missed. Frequently, the
symptoms were ascribed to flu-like viral syndromes. Sudden
deterioration is not a rare event in falciparum malaria and
dismissing febrile patients with a travel history that includes a
sojourn in malaria-endemic areas without thinking of and rul-
ing out this potentially lethal infection can be fatal. Once the
suspicion of a possible falciparum malaria is raised, the gen-
eral practitioner should clarify the exact (species) diagnosis
and the clinical assessment of the state of health of the pa-
tient.
The microscopic diagnosis is made by analyzing thick (de-
tection of parasitemia) and thin (species identification) blood
films. The detection of parasites can be very time-consuming,
especially in cases with low parasitemia, and identifying the
plasmodia species can be a very difficult task. Delayed rec-
ognition of P. falciparum led, at least in one of the fatal cases,
to an important delay of appropriate treatment. Therefore,
the microscopical diagnosis should be done or at least con-
firmed by an expert laboratory as fast as possible, at least
within 12 hours. One single negative result does not rule out
falciparum malaria, and blood analyses should be repeated
after 12–24 hours. For an immediate laboratory assessment,
physicians can use falciparum rapid tests as a helpful tool,
using a positive test result as a positive predictor for infection.
A recent meta-analysis has shown that rapid malaria tests are
useful in the assessment of febrile travelers returning from
Sub-Saharan Africa11 with the probability of P. falciparum
malaria estimated at 97% (CI, 92–99%) after a positive test
result. However, here also, blood should be brought or sent to
an expert laboratory, and one negative rapid test result does
not rule out falciparum malaria. A study in 2002 showed that,
if the clinical suspicion is high but microscopy is still delayed
or negative, there are clinical and laboratory predictors that
fully justify presumptive anti-malarial treatment.12 The
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strongest predictors for malaria infection in that study were
enlarged spleen (clinically assessed) and thrombocytopenia.
Regarding the state of health of the patient, every physician
should bear in mind that severe falciparum malaria can be a
sudden, life-threatening event. If falciparum malaria is sus-
pected and the patient is in a bad state of health, he must be
hospitalized, and a specialist in travel or tropical medicine
should be immediately consulted.
The median delay of 5 days between the onset of symptoms
and the establishment of the correct diagnosis is in line with
other observations with P. falciparum.13,14 Ideally, these de-
lays could be reduced to 1 or 2 days, if the patients would seek
immediately help in case of illness after travel and if physi-
cians were more aware of the disease and did not miss the
diagnosis. The median of 8 days that remained for the patients
to live after the symptom onset (and so only a median of 3
days from the correct diagnosis until death) suggest that the
patients were already in an advanced disease stage when cor-
rectly diagnosed and treated. Once severe malaria had devel-
oped, various vital organs were often affected, and even op-
timal intensive care did not prevent fatal outcome. The diffi-
culties in treating severe complications and multi-organ
failures underline the importance of prevention, ideally pre-
travel.
Typical patterns and key events identified in this study ex-
amined not only the travel period itself and the anti-malarial
interventions used (mosquito bite protection, chemoprophy-
laxis) but primarily the period before and after travel, includ-
ing the pre-travel communication between health care pro-
viders and travelers, the patient’s post-travel handling of ill-
ness, the correct establishing or ruling out of the diagnosis,
and the prompt treatment initiation. Interestingly, a recent
American study examining malaria-related deaths among US
travelers made equal or very similar observations as to how
these deaths could have been prevented.15 The study con-
cluded that health care providers must educate travelers
about malaria and keep in mind the importance of taking a
travel history, obtaining a blood film for suspected malaria,
and seeking expert advice. Furthermore, according to that
study, hospitals in the United States should have intravenous
quinidine gluconate on formulary because it is the only drug
available to treat severe malaria in the United States. In our
study, we did not observe any delay in treatment because of
unavailability of therapeutic agents.
The two Swiss nationals who were infected in Switzerland
died of airport malaria and transfusion-transmitted malaria,
respectively. Those very rare cases usually have much higher
CFRs, because the diagnosis is often excessively delayed be-
cause of the absence of a history of exposure to potentially
malaria-infected mosquito bites.16 Airport malaria occurs
mainly in hot summers favoring the survival of the mosqui-
toes. Physicians should keep these possibilities in the back of
their minds when treating patients with unclear fever or
thrombocytopenia.
We conclude that imported falciparum malaria is still a
frequent event in Switzerland and a challenge to travel health
practitioners and general practitioners. The main group at
high risk of death are non-immune Swiss and European na-
tionals traveling as tourists to Africa. On the other hand, the
numbers of falciparum cases is increased in travelers, mainly
of African origin, who have settled in Switzerland and whose
previously acquired semi-immunity has waned. Most infec-
tions with P. falciparum occur in Sub-Saharan Africa and can
be attributed to an incorrect use or non-use of prophylactic
measures. Despite increasing resistance, the three recom-
mended drug regimens (mefloquine, atovaquone/proguanil,
and doxycycline) are still highly effective in P. falciparum–
endemic areas. Travelers taking regular and recommended
chemoprophylaxis do not appear in the group of fatal infec-
tions. Many travelers do not use chemoprophylaxis, possibly
because of perceived adverse events or because they think
that malaria is readily curable. Prevention strategies must try
to reach these travelers. Travel operators and airlines can
facilitate this process. The attention of both travelers and
physicians should be raised even more to create a broad
awareness of the disease. General practitioners play a deci-
sive role before and after their patients travel to falciparum-
endemic areas. They should be aware of their importance in
preventing fatalities caused by malaria and update regularly
with the current and standardized information about drug
recommendations to avoid confusion and folklore-based
opinions among the travelers. Most important is providing
How a GP helps to prevent fatalities due to P. falciparum
Stage What to do
All three months • Update with standardized recommendations: (www.bag.admin.ch/infekt/reise/f (French), www.bag.admin.ch/
infekt/reise/d (German), www.safetravel.ch)
Pre-travel • Provide travelers with balanced up-to-date information of malaria, especially regarding
• Mosquito bite protection
• Recommended chemoprophylaxis and their possible side effects
• The finding of the best individual protection
• Instruct travelers how to react in case of illness during and after the travel
Post-travel • Think of malaria!
• Raise suspicion
• Clinical presentation
• Travel history
• Rapid dip-stick test and examination of thick blood film
• Microscopic Analysis by an expert laboratory within 12 hours!
• Malaria is not ruled out with one negative blood slide or rapid test
• If expert laboratory confirmation is still delayed and the clinical suspicion is high—begin treatment
• If the condition of the patient is indicative of severe infection: admit to hospital and seek specialist advice
• Notification
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individually tailored protection with concise advice on how to
handle an eventual infection. General practitioners who see
departing or returned travelers should not hesitate to draw on
specialist advice if they are not familiar with malaria. Most
important, post-travel is the advice to “think” malaria. Oth-
erwise, a malarial infection can easily be missed or misdiag-
nosed, particularly in the influenza season. These patients
may be unable to attend a follow-up visit if their condition has
worsened. Once the suspicion is raised, microscopic diagnosis
by an expert laboratory is required as soon as possible. One
negative blood slide does not rule out falciparum malaria and
has to be repeated within the next 12–24 hours. When expert
laboratory analysis is negative or still delayed, physicians
must begin antimalarial treatment if the clinical suspicion is
high (summary of positive indicators like clinical presenta-
tion, travel history, positive rapid dip-stick test). If the con-
dition of the patient is indicative of severe infection, hospital
admission with specialist advice is imperative. The most im-
portant findings of our study regarding the role of the general
practitioners have been put in the info box.
Further research on the knowledge, attitudes, and practices
of travelers and general practitioners regarding malaria pre-
vention and treatment is needed. What proportion of travel-
ers to malaria endemic areas seek pre-travel advice and do
not use the recommended chemoprophylaxis? What are the
exact reasons for non-adherence? The role and protective
effect of acquired semi-immunity needs clarification.. Kenya
was the main destination for the travelers with fatal outcomes.
Does this pinpoint Kenya as a main tourist destination of the
Swiss residents or could it suggest a higher prevalence of
mosquitoes/plasmodia or overly careless travel operators giv-
ing false advice in that region. The future role and applica-
tions for rapid diagnostic tests need further evaluation in the
travel clinic setting. Currently, they serve as a useful tool but
do not replace expert microscopy.
Reducing infections and fatalities among travelers is an
achievable goal, and the attitudes and practices of both trav-
elers and physicians need to be addressed.
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